Anti-phosphorylated histone H3 expression in Barrett's esophagus, low-grade dysplasia, high-grade dysplasia, and adenocarcinoma

Modern Pathology

Volumn 22, Issue 12, 2009, Pages 1612-1621

  Goodarzi, Mahmoud ^a   Correa, Arlene M ^a   Ajani, Jaffer A ^a   Swisher, Stephen G ^a   Hofstetter, Wayne L ^a   Guha, Sushovan ^a   Deavers, Michael T ^a   Rashid, Asif ^a   Maru, Dipen M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adenocarcinoma; Barrett's esophagus; Mitotic figure; PHH3

Indexed keywords

HISTONE ANTIBODY; HISTONE H3;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; DYSPLASIA; ENDOSCOPIC BIOPSY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; BIOPSY; CELL NUCLEUS; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOTIC INDEX; MUCOUS MEMBRANE; NEOPLASM STAGING; PHOSPHORYLATION; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 71149114660     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.133     Document Type: Article

References (34)

1. Odze RD. Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol 2006;59:1029-1038.
2. Kerkhof M, van dekken H, Steyerberg EW, et al. Grading of dysplasia in Barrett's oesophagus: substantial interobserver variation between general and gastrointestinal pathologists. Histopathology 2007;50: 920-927.
3. Montgomery E, Goldblum JR, Greenson JK, et al. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study. Hum Pathol 2001;32:379-388.
4. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-178.
5. Galipeau PC, Prevo LJ, Sanchez CA, et al. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J Natl Cancer Inst 1999;91:2087-2095.
6. Kerkhof M, Steyerberg EW, Kusters JG. Aneuploidy and high expression of p53 and Ki67 is associated with neoplastic progression in Barrett esophagus. Cancer Biomark 2008;4:1-10.
7. Reid B, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low and high-risk patient subsets. Am J Gastroenterol 2000;95: 1669-1676.
8. Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am J Surg Pathol 2006;30:871-877.
9. Lorinc E, Jakobsson B, Landberg G, et al. Ki67 and p53 immunohistochemistry reduces interobserver variation in assessment of Barrett's oesophagus. Histo-pathology 2005;46:642-648.
10. Parenti A, Leo G, Porzionato A, et al. Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis. Hum Pathol 2006;37:16-22.
11. Shinozaki M, Watanabe T, Kubota Y, et al. High proliferative activity is associated with dysplasia in ulcerative colitis. Dis Colon Rectum 2000;43:S34-S39.
12. Miracco C, Spina D, Vindigni C, et al. Cell proliferation patterns and p53 expression in gastric dysplasia. Int J Cancer 1995;62:149-154.
13. Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. Garland Science: New York, pp 213-215 (Chapter 4).
14. Hendzel MJ, Wei Y, Mancini MA. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-360.
15. Kim YJ, Ketter R, Steudel WI, et al. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol 2007;128:118-125.
16. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol 2004; 28:1532-1536.
17. Davidson EJ, Morris LS, Scott IS, et al. Minichromo-some maintenance (Mcm) proteins, cyclin B1 and D1, phosphohistone H3 and in situ DNA replication for functional analysis of vulvar intraepithelial neoplasia. Br J Cancer 2003;88:257-262.
18. Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol 1983;14:931-968.
19. Scheil-Bertram S, Lorenz D, Ell C, et al. Expression of alpha-methylacyl coenzyme A racemase in the dyspla-sia carcinoma sequence associated with Barrett's esophagus. Mod Pathol 2008;21:961-967.
20. Shi XY, Bhagwandeen B, Leong AS. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl Immunohistochem Mol Morphol 2008;16:447-452.
21. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102: 1212-1219.
22. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifiers a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-2848.
23. Sato F, Jin Z, Schulmann K, et al. Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS ONE 2008;3:e1890.
24. Hendzel MJ, Nishioka WK, Raymond Y, et al. Chro-matin condensation is not associated with apoptosis. J Biol Chem 1998;273:24470-24478.
25. Hong MK, Laskin WB, Herman BE, et al. Expansion of the Ki-67 proliferative compartment correlates with degree of dysplasia in Barrett's esophagus. Cancer 1995;75:423-429.
26. Olvera M, Wickramasinghe K, Brynes R, et al. Ki67 expression in different epithelial types in columnar lined oesophagus indicates varying levels of expanded and aberrant proliferative patterns. Histopathology 2005;47:132-140.
27. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
28. Baehner R, Weidner N. Enhanced mitotic figure counting in breast carcinomas using a mitosis-specific antibody: anti-phosphohistone-H3 (PHH3). Mod Pathol 2000;13:17A.
29. Coco D, Srivastava A, Sanchez C, et al. Surface mitoses are a predictor of cancer progression in Barrett's esophagus. Lab Invest 2009;89:127A.
30. Sirieix P, O'Donovan M, Brown J, et al. Surface expression of minichrome maintenance protein provides a novel method for detecting patients at risk for developing adenocarcinoma in Barrett's esophagus. Clin Cancer Res 2003;9:2560-2566.
31. Al-Nafussi AI, Hughes DE. Histological features of CIN 3 and their value in predicting invasive microinvasive squamous carcinoma. J Clin Pathol 1994;47:799-804.
32. Moritani S, Ioffe OB, Sagae S, et al. Mitotic activity and apoptosis in endocervical glandular lesions. Int J Gynecol Pathol 2002;21:125-133.
33. Witkiewicz A, Lee KR, Brodsky G, et al. Superficial (early) endocervical adenocarcinoma in situ: a study of 12 cases and comparison to conventional AIS. Am J Surg Pathol 2005;29:1609-1614.
34. Nasr MR, El-Zammar O. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions. Am J Dermatopathol 2008;30:117-122.